Lagos: The National Agency for Food and Drug Administration and Control (NAFDAC) has announced the recall of Mivacron and Nimbex injections due to potential safety risks linked to manufacturing deficiencies.
In a statement released Monday via its official X handle, NAFDAC disclosed that the injections were produced by Aspen Pharmacare Asia Limited.
The recall was triggered by safety concerns flagged by the Hong Kong Department of Health.
Specifically, one batch of Mivacron Injection (0.2%) and five batches of Nimbex Injection (2mg/mL) were affected.
NAFDAC explained that the manufacturer’s manual visual inspection process was found to be deficient, with investigations revealing that glass particles in ampoules may not have been fully detected.
The agency stressed that the voluntary recall was a precautionary measure to protect patients from potential quality issues.
Mivacron (mivacurium) and Nimbex (cisatracurium) are prescription medicines commonly used as adjuncts to general anaesthesia.
NAFDAC urged healthcare professionals and consumers to report suspected substandard medicines through its nearest office or via its e‑reporting platforms.
